Risedronate (Na)
Overview
Risedronate (Na) is a bisphosphate with similar properties to those of bisphosphonates in general. It inhibits bone resorption and is used in Paget`s diseaseof bone and in the treatment of post-menopausal osteoporosis to redce risk of vertebral or hip fractures.
Categories
- 18 Hormones and other endocrine drugs and contraceptives
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Risedronate (Na)'s dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 5 mg | 5 (5) | 24 hourly | PO | For treatment and prevention of Postmenopausal Osteoporosis: |
| 5 mg | 5 (5) | 24 hourly | PO | Treatment and Prevention of Glucocorticoid-Induced Osteoporosis: |
| 30 mg | 30 (30) | 24 hourly | PO | Treatment of Paget''s Disease :Retreatment may be considered (following post-treatment observation of at least 2 months) if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase. |
| 35 mg | 35 (35) | As recommended. | PO | Treatment to Increase Bone Mass in Men with Osteoporosis: Taken once a week. |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Risedronate (Na) is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Risedronate (Na) is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Risedronate (Na)
Back to top
Manufacturers of
Risedronate (Na)
in Pakistan
Back to top
Previous Drug Generic - Next Drug Generic